Amneal Pharmaceuticals
AMRX
19.65
-0.65
-3.18%
Amneal Pharmaceuticals
US · AMRX
#1854 by market cap
Listed 1970
19.65
-0.65
-3.18%
Live - 5344 symbols - heartbeat 416s ago
· 2026-10-08 07:35
Pre-market
19.65
0.00%
After-hours
19.65
0.00%
Overnight
19.76
+0.56%
- Market cap
- 6.28B
- P/E (TTM)i
- 40.94
- P/Bi
- 190.78
- EPSi
- 0.22
- Div yieldi
- 0.00%
- 52W posi
- 87%
Reader sentiment
Are you bullish or bearish on AMRX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 4.3 percentage points.
Institutional ownership
- Held by institutions
- 48.23% -4.30pp
- Institutions
- 379 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Individual/Insider38.19%
Mutual Fund34.78%
Hedge Fund5.80%
VC/PE Fund3.54%
Public Company1.98%
Government Pension Fund0.94%
Insurance Company0.55%
Private Company0.42%
Other13.71%
Top holders as of 2026-08-10
Tushar Patel
17.61% · 61.34M sh
BlackRock
7.63% · 26.56M sh
Akram Mahesh
5.90% · 20.56M sh
Dipan Patel
4.85% · 16.90M sh
Chirag Patel
4.53% · 15.79M sh
Chintu Patel
3.81% · 13.26M sh
TPG Capital, L.P.
3.54% · 12.33M sh
Vanguard Portfolio Management, LLC
3.48% · 12.14M sh
Rubric Capital Management LP
2.92% · 10.17M sh
Vanguard Capital Management, LLC
2.55% · 8.88M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 35 buys · 15 sells
| Name | Role | Stake |
|---|---|---|
| Tushar Patel | -- | 17.61% |
| Chirag Patel | Co-Founder, Co-CEO, President & Director | 4.53% |
| Chintu Patel | Co-Chief Executive Officer | 3.81% |
| Gautam Patel | Director | 0.55% |
| Paul Meister | Independent Chairperson | 0.24% |
| Anastasios Konidaris | Chief Financial Officer | 0.13% |
| Jeffrey George | Independent Director | 0.10% |
| Ted Nark | Independent Director | 0.09% |
| Shlomo Yanai | Independent Director | 0.09% |
| Nikita Shah | Executive Vice President | 0.07% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-16 | J. Buchi | Independent Director | Other Disposition | -20,445 | -- |
| 2026-09-10 | J. Buchi | Independent Director | Derivative Exercise and Retained | +20,445 | $14.45 |
| 2026-08-31 | Andrew Boyer | Executive VP & Chief Commercial Officer of Generics | Other Disposition | -80,000 | -- |
| 2026-08-20 | Andrew Boyer | Executive VP & Chief Commercial Officer of Generics | Other Disposition | -152,426 | -- |
| 2026-08-12 | John Kiely | Independent Director | Other Disposition | -10,000 | -- |
| 2026-08-12 | John Kiely | Independent Director | Open Market Disposition | -50,000 | $17.64 |
| 2026-08-11 | Nikita Shah | Executive Vice President | Open Market Disposition | -146,403 | $17.51 |
| 2026-08-11 | Jason Daly | Chief Legal Officer | Open Market Disposition | -216,613 | $17.40–17.70 |
| 2026-08-10 | J. Buchi | Independent Director | Open Market Disposition | -168,573 | $17.18 |
| 2026-08-09 | Chirag Patel | Co-Founder, Co-CEO, President & Director | Other Acquisition | +6,381,734 | -- |
| 2026-08-09 | Chintu Patel | Co-Chief Executive Officer | Other Acquisition | +6,381,734 | -- |
| 2026-08-09 | Tushar Patel | -- | Other Acquisition | +12,763,469 | -- |
| 2026-08-09 | Gautam Patel | Director | Other Acquisition | +283,632 | -- |
| 2026-05-10 | Deborah Autor | Independent Director | Open Market Disposition | -34,819 | $12.94 |
| 2026-05-06 | Paul Meister | Independent Chairperson | Derivative Exercise and Retained | +48,747 | -- |
| 2026-05-06 | J. Buchi | Independent Director | Derivative Exercise and Retained | +34,819 | -- |
| 2026-05-06 | Ted Nark | Independent Director | Derivative Exercise and Retained | +34,819 | -- |
| 2026-05-06 | Shlomo Yanai | Independent Director | Derivative Exercise and Retained | +34,819 | -- |
| 2026-05-06 | Jeffrey George | Independent Director | Derivative Exercise and Retained | +34,819 | -- |
| 2026-05-06 | Gautam Patel | Director | Derivative Exercise and Retained | +34,819 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:35:43 · For reference only, not investment advice and not tailored to your situation.